Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
CancerRespiratory

PUBLISHER: Grand View Research | PRODUCT CODE: 1679375

Cover Image

PUBLISHER: Grand View Research | PRODUCT CODE: 1679375

Lung Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Immunotherapy, Radiation Therapy), By End-use (Hospitals, Specialty Clinics), By Region (North America, Europe), And Segment Forecasts, 2025 - 2030

PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF (Single User License)
USD 5950
Printable PDF (5-User License)
USD 6950
Printable PDF (Enterprise License)
USD 8950

Add to Cart

Description

Table of Contents

List of Tables

Lung Adenocarcinoma Treatment Market Growth & Trends:

The global lung adenocarcinoma treatment market size is expected to reach USD 11.18 billion by 2030, registering a CAGR of 10.7% from 2025 to 2030, according to a new report by Grand View Research, Inc. This market offers a range of therapeutic options, technologies, and services aimed at managing and treating lung adenocarcinoma, which is a subtype of non-small cell lung cancer (NSCLC).

The rise in smoking rates in certain regions and environmental factors such as air pollution and occupational hazards are key growth drivers for market growth. As more individuals are diagnosed with lung adenocarcinoma, there is a corresponding demand for effective treatment options.

Increased awareness about lung cancer symptoms and risk factors has significantly influenced the market. Public health campaigns aimed at educating populations about smoking cessation and early detection led to more individuals seeking medical attention sooner after experiencing symptoms.

In October 2023, Bristol Myers Squibb acquired Mirati for USD 58.00 per share, totaling USD 4.8 billion in equity value, potentially rising to USD 5.8 billion with contingent value rights, including KRAZATI (adagrasib), a KRASG12C inhibitor for advanced non-small cell lung cancer.

Lung Adenocarcinoma Treatment Market Report Highlights:

  • The chemotherapy segment accounted for the largest revenue share of 36% in 2024. This is primarily due to its established role in lung cancer management and ongoing advancements in treatment regimens.
  • The immunotherapy segment is expected to witness the fastest growth, with a projected CAGR of 13.5% over the forecast period. The rising prevalence of lung adenocarcinoma has increased the demand for advanced treatment options that offer better efficacy and safety compared to traditional therapies such as chemotherapy and radiation.
  • Hospitals accounted for the largest revenue share of 63.9% in 2024, driven by their comprehensive infrastructure and ability to provide a wide range of advanced cancer treatments.
  • The specialty clinics segment is expected to grow at the fastest CAGR over the forecast period. This growth is driven by the rising demand for personalized and targeted therapies, along with increasing patient awareness of lung cancer treatment options.
  • North America lung adenocarcinoma treatment market held the largest revenue share of 39.5% in 2024, driven by the rising incidence of lung adenocarcinoma and a strong focus on innovation in treatment approaches.
Show more
Product Code: GVR-4-68040-428-6

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. End use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lung Adenocarcinoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Lung adenocarcinoma treatment market: Type Business Analysis

  • 4.1. Treatment Market Share, 2024 & 2030
  • 4.2. Treatment Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 4.4. Chemotherapy
    • 4.4.1. Chemotherapy Market, 2018 - 2030 (USD Million)
  • 4.5. Targeted therapy
    • 4.5.1. Targeted Therapy Market, 2018 - 2030 (USD Million)
  • 4.6. Immunotherapy
    • 4.6.1. Immunotherapy Market, 2018 - 2030 (USD Million)
  • 4.7. Radiation therapy
    • 4.7.1. Radiation Therapy Market, 2018 - 2030 (USD Million)
  • 4.8. Other
    • 4.8.1. Other Market, 2018 - 2030 (USD Million)

Chapter 5. Lung adenocarcinoma treatment market: End use Business Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. End Use Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 5.4. Hospitals
    • 5.4.1. Hospitals Market, 2018 - 2030 (USD Million)
  • 5.5. Specialty Clinics
    • 5.5.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
  • 5.6. Other
    • 5.6.1. Other Market, 2018 - 2030 (USD Million)

Chapter 6. Lung adenocarcinoma treatment market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
  • 6.4. North America
    • 6.4.1. North America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.4.2. U.S.
      • 6.4.2.1. Key Country Dynamics
      • 6.4.2.2. Regulatory Framework
      • 6.4.2.3. Competitive Insights
      • 6.4.2.4. U.S. Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Canada
      • 6.4.3.1. Key Country Dynamics
      • 6.4.3.2. Regulatory Framework
      • 6.4.3.3. Competitive Insights
      • 6.4.3.4. Canada Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. Mexico
      • 6.4.4.1. Key Country Dynamics
      • 6.4.4.2. Regulatory Framework
      • 6.4.4.3. Competitive Insights
      • 6.4.4.4. Mexico Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Europe
    • 6.5.1. Europe Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.5.2. UK
      • 6.5.2.1. Key Country Dynamics
      • 6.5.2.2. Regulatory Framework
      • 6.5.2.3. Competitive Insights
      • 6.5.2.4. UK Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Germany
      • 6.5.3.1. Key Country Dynamics
      • 6.5.3.2. Regulatory Framework
      • 6.5.3.3. Competitive Insights
      • 6.5.3.4. Germany Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.4. France
      • 6.5.4.1. Key Country Dynamics
      • 6.5.4.2. Regulatory Framework
      • 6.5.4.3. Competitive Insights
      • 6.5.4.4. France Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.5. Italy
      • 6.5.5.1. Key Country Dynamics
      • 6.5.5.2. Regulatory Framework
      • 6.5.5.3. Competitive Insights
      • 6.5.5.4. Italy Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.6. Spain
      • 6.5.6.1. Key Country Dynamics
      • 6.5.6.2. Regulatory Framework
      • 6.5.6.3. Competitive Insights
      • 6.5.6.4. Spain Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.7. Norway
      • 6.5.7.1. Key Country Dynamics
      • 6.5.7.2. Regulatory Framework
      • 6.5.7.3. Competitive Insights
      • 6.5.7.4. Norway Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.8. Denmark
      • 6.5.8.1. Key Country Dynamics
      • 6.5.8.2. Regulatory Framework
      • 6.5.8.3. Competitive Insights
      • 6.5.8.4. Denmark Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.5.9. Sweden
      • 6.5.9.1. Key Country Dynamics
      • 6.5.9.2. Regulatory Framework
      • 6.5.9.3. Competitive Insights
      • 6.5.9.4. Sweden Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Asia Pacific
    • 6.6.1. Asia Pacific Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.6.2. Japan
      • 6.6.2.1. Key Country Dynamics
      • 6.6.2.2. Regulatory Framework
      • 6.6.2.3. Competitive Insights
      • 6.6.2.4. Japan Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. China
      • 6.6.3.1. Key Country Dynamics
      • 6.6.3.2. Regulatory Framework
      • 6.6.3.3. Competitive Insights
      • 6.6.3.4. China Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. India
      • 6.6.4.1. Key Country Dynamics
      • 6.6.4.2. Regulatory Framework
      • 6.6.4.3. Competitive Insights
      • 6.6.4.4. India Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. South Korea
      • 6.6.5.1. Key Country Dynamics
      • 6.6.5.2. Regulatory Framework
      • 6.6.5.3. Competitive Insights
      • 6.6.5.4. South Korea Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.6. Australia
      • 6.6.6.1. Key Country Dynamics
      • 6.6.6.2. Regulatory Framework
      • 6.6.6.3. Competitive Insights
      • 6.6.6.4. Australia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.6.7. Thailand
      • 6.6.7.1. Key Country Dynamics
      • 6.6.7.2. Regulatory Framework
      • 6.6.7.3. Competitive Insights
      • 6.6.7.4. Thailand Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.7. Latin America
    • 6.7.1. Latin America Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.7.2. Brazil
      • 6.7.2.1. Key Country Dynamics
      • 6.7.2.2. Regulatory Framework
      • 6.7.2.3. Competitive Insights
      • 6.7.2.4. Brazil Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.7.3. Argentina
      • 6.7.3.1. Key Country Dynamics
      • 6.7.3.2. Regulatory Framework
      • 6.7.3.3. Competitive Insights
      • 6.7.3.4. Argentina Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 6.8. MEA
    • 6.8.1. MEA Lung Adenocarcinoma Treatment Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 6.8.2. South Africa
      • 6.8.2.1. Key Country Dynamics
      • 6.8.2.2. Regulatory Framework
      • 6.8.2.3. Competitive Insights
      • 6.8.2.4. South Africa Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.3. Saudi Arabia
      • 6.8.3.1. Key Country Dynamics
      • 6.8.3.2. Regulatory Framework
      • 6.8.3.3. Competitive Insights
      • 6.8.3.4. Saudi Arabia Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.4. UAE
      • 6.8.4.1. Key Country Dynamics
      • 6.8.4.2. Regulatory Framework
      • 6.8.4.3. Competitive Insights
      • 6.8.4.4. UAE Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.8.5. Kuwait
      • 6.8.5.1. Key Country Dynamics
      • 6.8.5.2. Regulatory Framework
      • 6.8.5.3. Competitive Insights
      • 6.8.5.4. Kuwait Lung Adenocarcinoma Treatment Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Participant Overview
  • 7.2. Company Market Position Analysis
  • 7.3. Company Categorization
  • 7.4. Strategy Mapping
  • 7.5. Company Profiles/Listing
    • 7.5.1. Pfizer Inc.
      • 7.5.1.1. Overview
      • 7.5.1.2. Financial Performance
      • 7.5.1.3. Product Benchmarking
      • 7.5.1.4. Strategic Initiatives
    • 7.5.2. AstraZeneca
      • 7.5.2.1. Overview
      • 7.5.2.2. Financial Performance
      • 7.5.2.3. Product Benchmarking
      • 7.5.2.4. Strategic Initiatives
    • 7.5.3. Bristol-Myers Squibb Company
      • 7.5.3.1. Overview
      • 7.5.3.2. Financial Performance
      • 7.5.3.3. Product Benchmarking
      • 7.5.3.4. Strategic Initiatives
    • 7.5.4. Eli Lilly and Company
      • 7.5.4.1. Overview
      • 7.5.4.2. Financial Performance
      • 7.5.4.3. Product Benchmarking
      • 7.5.4.4. Strategic Initiatives
    • 7.5.5. Boehringer Ingelheim International GmbH
      • 7.5.5.1. Overview
      • 7.5.5.2. Financial Performance
      • 7.5.5.3. Product Benchmarking
      • 7.5.5.4. Strategic Initiatives
    • 7.5.6. Novartis AG
      • 7.5.6.1. Overview
      • 7.5.6.2. Financial Performance
      • 7.5.6.3. Product Benchmarking
      • 7.5.6.4. Strategic Initiatives
    • 7.5.7. Merck KGaA (EMD Serono)
      • 7.5.7.1. Overview
      • 7.5.7.2. Financial Performance
      • 7.5.7.3. Product Benchmarking
      • 7.5.7.4. Strategic Initiatives
    • 7.5.8. AbbVie Inc.
      • 7.5.8.1. Overview
      • 7.5.8.2. Financial Performance
      • 7.5.8.3. Product Benchmarking
      • 7.5.8.4. Strategic Initiatives
    • 7.5.9. Astellas Pharma Inc.
      • 7.5.9.1. Overview
      • 7.5.9.2. Financial Performance
      • 7.5.9.3. Product Benchmarking
      • 7.5.9.4. Strategic Initiatives
    • 7.5.10. F. Hoffmann-La Roche Ltd
      • 7.5.10.1. Overview
      • 7.5.10.2. Financial Performance
      • 7.5.10.3. Product Benchmarking
      • 7.5.10.4. Strategic Initiatives
Show more
Product Code: GVR-4-68040-428-6

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global lung adenocarcinoma treatment market, by region, 2018 - 2030 (USD Million)
  • Table 4 Global lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 5 Global lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 8 North America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 9 U.S. lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 U.S. lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 11 Canada lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 12 Canada lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Mexico lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 14 Mexico lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 15 Europe lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 16 Europe lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 18 UK lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 19 UK lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 20 Germany lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 21 Germany lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 22 France lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 France lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 24 Italy lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 25 Italy lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 26 Spain lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 27 Spain lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 28 Norway lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Norway lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 30 Denmark lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 31 Denmark lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Sweden lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 33 Sweden lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 37 Japan lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Japan lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 39 China lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 40 China lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 41 India lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 42 India lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 43 Australia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 44 Australia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 45 South Korea lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 46 South Korea lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Thailand lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 Thailand lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 49 Latin America lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 50 Latin America lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Latin America lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 52 Brazil lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 53 Brazil lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Argentina lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 55 Argentina lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 56 Middle East & Africa lung adenocarcinoma treatment market, by country, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 59 South Africa lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 South Africa lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 63 UAE lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 64 UAE lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)
  • Table 65 Kuwait lung adenocarcinoma treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 66 Kuwait lung adenocarcinoma treatment market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lung Adenocarcinoma Treatment Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Treatment and end use outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Lung adenocarcinoma treatment market dynamics
  • Fig. 12 Lung adenocarcinoma treatment market: Porter's five forces analysis
  • Fig. 13 Lung adenocarcinoma treatment market: PESTLE analysis
  • Fig. 14 Lung adenocarcinoma treatment market: Treatment segment dashboard
  • Fig. 15 Lung adenocarcinoma treatment market: Treatment market share analysis, 2024 & 2030
  • Fig. 16 Chemotherapy market, 2018 - 2030 (USD Million)
  • Fig. 17 Targeted therapy market, 2018 - 2030 (USD Million)
  • Fig. 18 Immunotherapy market, 2018 - 2030 (USD Million)
  • Fig. 19 Radiation therapy market, 2018 - 2030 (USD Million)
  • Fig. 20 Other market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung adenocarcinoma treatment market: End use segment dashboard
  • Fig. 22 Lung adenocarcinoma treatment market: End use market share analysis, 2024 & 2030
  • Fig. 23 Hospitals market, 2018 - 2030 (USD Million)
  • Fig. 24 Specialty clinics market, 2018 - 2030 (USD Million)
  • Fig. 25 Other market, 2018 - 2030 (USD Million)
  • Fig. 26 Lung Adenocarcinoma Treatment Market revenue, by region
  • Fig. 27 Regional marketplace: Key takeaways
  • Fig. 28 North America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 29 U.S. country dynamics
  • Fig. 30 U.S. lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 31 Canada country dynamics
  • Fig. 32 Canada lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 33 Mexico country dynamics
  • Fig. 34 Mexico lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 35 Europe lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 36 UK country dynamics
  • Fig. 37 UK lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 38 Germany country dynamics
  • Fig. 39 Germany lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 40 France country dynamics
  • Fig. 41 France lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 42 Italy country dynamics
  • Fig. 43 Italy lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 Spain country dynamics
  • Fig. 45 Spain lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Norway country dynamics
  • Fig. 47 Norway lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 Sweden country dynamics
  • Fig. 49 Sweden lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Denmark country dynamics
  • Fig. 51 Denmark lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 53 Japan country dynamics
  • Fig. 54 Japan lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 55 China country dynamics
  • Fig. 56 China lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 57 India country dynamics
  • Fig. 58 India lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 59 Australia country dynamics
  • Fig. 60 Australia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 South Korea country dynamics
  • Fig. 62 South Korea lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 Thailand country dynamics
  • Fig. 64 Thailand lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 Latin America lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 66 Brazil country dynamics
  • Fig. 67 Brazil lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 68 Argentina country dynamics
  • Fig. 69 Argentina lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 70 MEA lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 South Africa country dynamics
  • Fig. 72 South Africa lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Saudi Arabia country dynamics
  • Fig. 74 Saudi Arabia lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 75 UAE country dynamics
  • Fig. 76 UAE lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 77 Kuwait country dynamics
  • Fig. 78 Kuwait lung adenocarcinoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 Company categorization
  • Fig. 80 Company market position analysis
  • Fig. 81 Strategic framework
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!